BPG is committed to discovery and dissemination of knowledge
Featured Articles
5/19/2023 10:34:41 AM | Browse: 147 | Download: 462
Publication Name World Journal of Clinical Oncology
Manuscript ID 83164
Country United States
Received
2023-01-09 21:23
Peer-Review Started
2023-01-09 21:25
To Make the First Decision
Return for Revision
2023-01-31 08:53
Revised
2023-02-28 16:49
Second Decision
2023-04-21 03:02
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2023-04-21 08:03
Articles in Press
2023-04-21 08:03
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2023-05-11 09:16
Publish the Manuscript Online
2023-05-19 06:25
ISSN 2218-4333 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Minireviews
Article Title Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer
Manuscript Source Invited Manuscript
All Author List Aya Abunada, Zaid Sirhan, Anita Thyagarajan and Ravi P Sahu
Funding Agency and Grant Number
Funding Agency Grant Number
Elsa U. Pardee Foundation grant 671432
NIH R21 grant ES033806
Corresponding Author Ravi P Sahu, BSc, MSc, PhD, Assistant Professor, Department of Pharmacology and Toxicology, Boonshoft School of Medicine Wright State University, 230 Health Sciences Bldg, 3640 Colonel Glenn Hwy, Dayton, OH 45435, United States. ravi.sahu@wright.edu
Key Words Human epidermal growth factor receptor-2 positive breast cancer; Tyrosine kinase inhibitors; Lapatinib; Pyrotinib; Tucatinib; Trastuzumab
Core Tip Newly published randomized controlled trials within the past two years have provided compelling evidence on the use of tyrosine kinase inhibitors (TKIs) such as Lapatinib, Pyrotinib, Neratinib, Tucatinib, Ruxolitinib, and Afatinib. Several of these agents were found to offer better outcomes in terms of progression-free survival when combined with other agents. While some TKIs, namely Lapatinib, and Neratinib, are supported with a large amount of data than others, the medical literature still lacks substantial evidence to draw a clinical conclusion that could modify/add to the present recommendations in human epidermal growth factor receptor-2 positive breast cancer treatment guidelines.
Publish Date 2023-05-19 06:25
Citation Abunada A, Sirhan Z, Thyagarajan A, Sahu RP. Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer. World J Clin Oncol 2023; 14(5): 198-202
URL https://www.wjgnet.com/2218-4333/full/v14/i5/198.htm
DOI https://dx.doi.org/10.5306/wjco.v14.i5.198
Full Article (PDF) WJCO-14-198.pdf
Full Article (Word) WJCO-14-198.docx
Manuscript File 83164_Auto_Edited-JLW.docx
Answering Reviewers 83164-Answering reviewers.pdf
Audio Core Tip 83164-Audio core tip.m4a
Conflict-of-Interest Disclosure Form 83164-Conflict-of-interest statement.pdf
Copyright License Agreement 83164-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s) 83164-Grant application form(s).pdf
Peer-review Report 83164-Peer-review(s).pdf
Scientific Misconduct Check 83164-Bing-Li L-2.png
Scientific Editor Work List 83164-Scientific editor work list.pdf